SARS-CoV-2, the virus responsible for COVID-19, has a genome made of RNA (a nucleic acid similar to DNA) that can mutate, potentially making the disease more transmissible, and more lethal. Most countries have monitored the rise of mutated strains using a technique called next generation sequencing (NGS), which is time-consuming, expensive and requires skilled personnel. Sometimes the mutations to the virus are so small that they can only be detected using NGS. Finding cheaper, simpler and faster SARS-CoV-2 tests that can reliably detect mutated forms of the virus is crucial for public health authorities to monitor and manage the spread of the virus.

Lateral flow tests (the same technology used in many pregnancy tests) are typically cheap, fast and simple to use. Typically, lateral flow assay strips have a band of immobilised antibodies that bind to a specific protein (or antigen). If a sample contains antigen molecules, these will bind to the immobilised antibodies, causing a chemical reaction that changes the colour of the strip and giving a positive result. However, lateral flow tests that use antibodies cannot easily detect nucleic acids, such as DNA or RNA, let alone mutations in them.

To overcome this limitation, lateral flow assays can be used to detect a protein called Cas9, which, in turn, is able to bind to nucleic acids with specific sequences. Small changes in the target sequence change how well Cas9 binds to it, meaning that, in theory, this approach could be used to detect small mutations in the SARS-CoV-2 virus.

Kumar et al. made a lateral flow test that could detect a Cas9 protein that binds to a nucleic acid sequence found in a specific mutant strain of SARS-CoV-2. This Cas9 was highly sensitive to changes in its target sequence, so a small mutation in the target nucleic acid led to the protein binding less strongly, and the signal from the lateral flow test being lost. This meant that the lateral flow test designed by Kumar et al. could detect mutations in the SARS-CoV-2 virus at a fraction of the price of NGS approaches if used only for diagnosis. The lateral flow test was capable of detecting mutant viruses in patient samples too, generating a colour signal within an hour of a positive sample being run through the assay.

The test developed by Kumar et al. could offer public health authorities a quick and cheap method to monitor the spread of mutant SARS-CoV-2 strains; as well as a way to determine vaccine efficacy against new strains.

Testing and isolating SARS-CoV-2-positive cases has been one of the main strategies for controlling the rise and spread of the coronavirus pandemic that has affected about 157 million people and 3 million deaths all over the world (World Health Organization, WHO). Like all other viruses, the SARS-CoV-2 genome has undergone several mutations during its passage through the human host, and the positive or negative impact of most of them on virus transmission and immune escape are still under investigation (Rabi et al., 2020; Pachetti et al., 2020; Korber et al., 2020; Zhou et al., 2021).

In December 2020, health authorities in the United Kingdom had reported the emergence of a new SARS-CoV-2 variant (lineage B.1.1.7) that is phylogenetically distinct from other circulating strains in the region. With 23 mutations, this variant had rapidly replaced former SARS-CoV-2 lineages occurring in the region and has been established to have greater transmissibility through modeling and clinical correlation studies (Chand, 2020; Horby et al., 2021; Davies et al., 2021; Volz et al., 2021). Subsequently, the South African and Brazilian authorities have also reported variants (B.1.351 and P.1, respectively) that have been associated with a higher viral load in preliminary studies (Tegally et al., 2020; Faria et al., 2021). Till May 2021, at least 13 emerging SARS-CoV-2 lineages with multiple mutations have been reported from sequencing efforts across the globe (CDC, 2021). Variants in lineages of the SARS-CoV-2 genome have been classified either as Variants of Concern (VOC) or Variants of Interest (VOI). Among these, the VOCs have shown an indication of higher severity, transmissibility, and impact on pandemic spread from ongoing studies. VOIs have limited evidence for the same currently but are being monitored for potential impact in the future. Till May 2021, at least five lineages (B.1.1.7, P.1, B.1.351, B.1.427, and B.1.429) have been classified as VOCs and are being investigated for their susceptibility to diagnosis, response to vaccines, and correlation with disease severity and transmission (CDC, 2021).

As air travel has resumed in most countries post lockdown, infected individuals harboring these mutations have been detected in countries far away from their origin, generating concerns about greater disease incidence unless these cases are recognized and isolated. That is particularly important as vaccine roll-out has been initiated in several countries, and the studies about vaccine efficacy against the new variants are only in their infancy.

Among the diagnostic methods that have been employed for identifying coronavirus infected cases, qRT-PCR has been the most widely adopted nucleic-acid-based test due to its ability to identify even low copy numbers of viral RNA in patient samples and has been considered as a gold standard in diagnosis (Mackay, 2002; Carter et al., 2020). However, probe-based qRT PCR assays rely on amplification of a target gene with real-time analysis of DNA copy numbers and are generally not suited for genotyping point mutations associated with novel CoV2 variants (Afzal, 2020; Yin, 2020; Vandenberg et al., 2021). Although strategies such as Amplification Refractory Mutation System-quantitative PCR (ARMS-qPCR) have been described in the literature for genotyping mutations in nucleic acids, these require substantial design and validation for reproducible readouts and hence are not routinely used for clinical diagnosis (Little, 2001). Similarly, antigen-based SARS-CoV-2 assays which have lower sensitivity than qPCR have not yet been reported to specifically identify mutant variants. In the absence of any true diagnostic test for the variants, most countries have resorted to next-generation sequencing of patient samples both for understanding the evolution of mutations in the virus as well as detecting the variants in suspected individuals (Vandenberg et al., 2021). Using sequencing for routine diagnosis greatly increases both the time and cost of identifying positive individuals (Jayamohan et al., 2021).

We and several others have documented the applicability of CRISPR diagnostics (CRISPRDx) for identifying CoV2 signatures in patient samples (Broughton et al., 2020; Patchsung et al., 2020; Ding et al., 2020; Joung et al., 2020; Fozouni et al., 2021; Guo et al., 2020; Lucia et al., 2020; Wang et al., 2021; Azhar et al., 2021). Using the Cas9 from Francisella novicida (FnCas9), we have recently reported the development of the FELUDA (FnCas9 Editor Linked Uniform Detection Assay) platform for SARS-CoV-2 diagnosis with similar accuracy as the gold standard qPCR test (Azhar et al., 2021). The assay which is performed on a Lateral Flow strip generates a visual readout within an hour that is quantifiable using a smartphone-based application. Since FnCas9 has a very high intrinsic specificity to point mismatches in the target (Acharya et al., 2019), we speculated that the enzyme can also be used for detecting SARS-CoV-2 variants on a paper strip with high accuracy. In this report, we introduce RAY (Rapid variant AssaY), a paper-strip based platform to identify mutational signatures of the coronavirus variants in a sample eliminating the need for sequencing-based diagnostics. RAY can successfully detect both SARS-CoV-2 infection as well as the presence of the common N501Y mutation present across the majority of VOCs described so far and distinguish it from the parent CoV2 lineage. Thus, it can be employed as a primary surveillance method for isolating cases belonging to these groups and can enable the initiation of appropriate management protocols.

Currently, deep-sequencing of patient samples is being routinely done by health authorities in various countries to track and isolate cases containing the SARS-CoV-2 variants (Meredith et al., 2020; Oude Munnink et al., 2020; McNamara et al., 2020; Rockett et al., 2020; Bhoyar et al., 2021). The accuracy of variant calling in any sequencing platform is dependent on the very high quality and coverage of reads to the reference genome. Since the process from sample to sequence consists of multiple steps, low viral titres can be missed out during sequencing assays for variant calling. The RAY pipeline uses an amplification step followed by enzymatic binding and is reproducible across a wide range of viral titres tested.

The main advantage of sequencing COVID-19 samples is the generation of cumulative information about all mutations co-existing in a given variant (Chiu and Miller, 2019 and Vandenberg et al., 2021). This information is valuable to track and trace how lineages evolve and has led to the identification of mutations in the first place. RAY can identify only known VOCs and is therefore useful as a diagnostic tool for the early detection of variant signatures in a sample. For example, determining whether a sample belongs to the South African lineage through E484K specific RAY can allow early quarantine of the patient and prevent the spreading of a highly transmissible variant. Similarly, identifying a WT sample rapidly through RAY negates the necessity of sequencing such a sample thereby reducing the cost of the associated sequencing exercise. Together, this can ease the burden of surveillance and ensure both rapid disease control measures as well as the identification of newer variants efficiently.

In the current format (lateral flow assay), RAY has limitations in multiplexing several VOC candidates in a single assay. Although longer amplicons can be used to identify multiple mutations that appear close to each other, we observed a drop in sensitivity probably due to reduced PCR efficiency for longer amplicons. Similarly, to increase the throughput of the assay, converting the readout into a fluorescence-based mode might be beneficial.

Perhaps, the most imperative area of improvement for RAY is increasing the number of possible mutations that can be targeted. The necessity of an NGG PAM at a fixed position away from the position of the target mutation limits the total number of targets that RAY can identify. This can be significantly expanded by systematically exploring more sites in the sgRNA where a mutation weakens the enzyme:substrate interaction. Alternatively, engineering the enzyme to generate PAM-flexible versions can be considered.

Routine sequencing of patient samples for disease surveillance is fraught with issues such as cost, logistics, and turnaround times. A typical deep sequencing cost per sample is several orders of magnitude higher than RAY (which costs ~7 USD per sample, Supplementary file 3) and the minimum turnaround time for sequencing is 36 hr. Importantly, sequencing runs are generally done on pooled samples to save on cost, workforce, and machine time, all of which necessitate the advent of alternate solutions that can identify variants through a simple pipeline. RAY -on the contrary- is scalable to any number of samples at a given time.

Sequencing also generates a large amount of data and requires physical storage and high-performance computing methodologies to record, analyze and interpret the data (Chiu and Miller, 2019 and Vandenberg et al., 2021). In addition, dedicated personnel with a substantial understanding of sequence analysis and programming skills are necessary for identifying variants within reads generated from a sample. In contrast, RAY uses a visual readout on a paper strip leading to a binary decision about the sample. The automated image acquisition and recording through a smartphone app allows operators with a minimum skill set to process samples. This has the advantage of rapid screening, particularly at the point of care settings.

In this study, we report the development of a CRISPR diagnostic platform for detecting the major VOCs in the SARS-CoV-2 genome. The outcomes of this platform can be extended to other pathogenic SNVs and can provide a robust solution for rapid variant calling in patient samples. Considering the rise and spread of mutated lineages of the virus in multiple countries, it is imperative to develop technologies that can quickly and accurately detect these variants. Since the first-generation vaccines against SARS-CoV-2 have been developed against the parent strain, careful assessment of the variant lineages and their response to the vaccine will become imperative during the course of the pandemic (Fontanet et al., 2021; Walensky et al., 2021). Novel variants, particularly those correlated with adverse disease manifestation, need to be controlled so that these do not spread rampantly across populations. Testing and isolating them will thus continue to be at the forefront of disease control measures.

Sequencing data associated with the manuscript have been deposited to GISAID with the following numbers: EPI_ISL_911542, EPI_ISL_911532, EPI_ISL_911543, EPI_ISL_911533, EPI_ISL_911544, EPI_ISL_911534, EPI_ISL_911545, EPI_ISL_911535, EPI_ISL_911546, EPI_ISL_911536, EPI_ISL_911547, EPI_ISL_911537, EPI_ISL_911538, EPI_ISL_911540, EPI_ISL_911541, EPI_ISL_911539.

1. 1. Pandey R
   2. Kanakan A
   3. Janani SV
   4. Maurya R
   5. Murali AS
   6. Sahni S
   7. Khan A
   8. Chattopadhyay P
   9. Devi P
   10. Mehta P
   11. Kumar A
   12. Rawat N

   (2021) GISAID

   ID EPI_ISL_911542. SARS CoV-2 sequencing data.

   https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_22_41_qw71ju_3lh56ce0a1a5/EPI_ISL_911542.fasta
2. 1. Pandey R
   2. Kanakan A
   3. Janani SV
   4. Maurya R
   5. Murali AS
   6. Sahni S
   7. Khan A
   8. Chattopadhyay P
   9. Devi P
   10. Mehta P
   11. Kumar A
   12. Rawat N

   (2021) GISAID

   ID EPI_ISL_911532. SARS CoV-2 sequencing data.

   https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_12_qw71ju_3pd56ce0931d/EPI_ISL_911532.fasta
3. 1. Pandey R
   2. Kanakan A
   3. Janani SV
   4. Maurya R
   5. Murali AS
   6. Sahni S
   7. Khan A
   8. Chattopadhyay P
   9. Devi P
   10. Mehta P
   11. Kumar A
   12. Rawat N

   (2021) GISAID

   ID EPI_ISL_911543. SARS CoV-2 sequencing data.

   https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_13_qw71ju_3pgs6ce09282/EPI_ISL_911543.fasta
4. 1. Pandey R
   2. Kanakan A
   3. Janani SV
   4. Maurya R
   5. Murali AS
   6. Sahni S
   7. Khan A
   8. Chattopadhyay P
   9. Devi P
   10. Mehta P
   11. Kumar A
   12. Rawat N

   (2021) GISAID

   ID EPI_ISL_911533. SARS CoV-2 sequencing data.

   https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_14_qw71ju_3pj26ce09266/EPI_ISL_911533.fasta
5. 1. Pandey R
   2. Kanakan A
   3. Janani SV
   4. Maurya R
   5. Murali AS
   6. Sahni S
   7. Khan A
   8. Chattopadhyay P
   9. Devi P
   10. Mehta P
   11. Kumar A
   12. Rawat N

   (2021) GISAID

   ID EPI_ISL_911544. SARS CoV-2 sequencing data.

   https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_16_qw71ju_3pml6ce091cf/EPI_ISL_911544.fasta
6. 1. Pandey R
   2. Kanakan A
   3. Janani SV
   4. Maurya R
   5. Murali AS
   6. Sahni S
   7. Khan A
   8. Chattopadhyay P
   9. Devi P
   10. Mehta P
   11. Kumar A
   12. Rawat N

   (2021) GISAID

   ID EPI_ISL_911534. SARS CoV-2 sequencing data.

   https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_16_qw71ju_3ppp6ce0916e/EPI_ISL_911534.fasta
7. 1. Pandey R
   2. Kanakan A
   3. Janani SV
   4. Maurya R
   5. Murali AS
   6. Sahni S
   7. Khan A
   8. Chattopadhyay P
   9. Devi P
   10. Mehta P
   11. Kumar A
   12. Rawat N

   (2021) GISAID

   ID EPI_ISL_911545. SARS CoV-2 sequencing data.

   https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_17_qw71ju_3pym6ce0905a/EPI_ISL_911545.fasta
8. 1. Pandey R
   2. Kanakan A
   3. Janani SV
   4. Maurya R
   5. Murali AS
   6. Sahni S
   7. Khan A
   8. Chattopadhyay P
   9. Devi P
   10. Mehta P
   11. Kumar A
   12. Rawat N

   (2021) GISAID

   ID EPI_ISL_911535. SARS CoV-2 sequencing data.

   https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_18_qw71ju_3q0b6ce0957b/EPI_ISL_911535.fasta
9. 1. Pandey R
   2. Kanakan A
   3. Janani SV
   4. Maurya R
   5. Murali AS
   6. Sahni S
   7. Khan A
   8. Chattopadhyay P
   9. Devi P
   10. Mehta P
   11. Kumar A
   12. Rawat N

   (2021) GISAID

   ID EPI_ISL_911546. SARS CoV-2 sequencing data.

   https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_19_qw71ju_3q2n6ce09531/EPI_ISL_911546.fasta
10. 1. Pandey R
    2. Kanakan A
    3. Janani SV
    4. Maurya R
    5. Murali AS
    6. Sahni S
    7. Khan A
    8. Chattopadhyay P
    9. Devi P
    10. Mehta P
    11. Kumar A
    12. Rawat N

    (2021) GISAID

    ID EPI_ISL_911536. SARS CoV-2 sequencing data.

    https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_19_qw71ju_3q6d6ce094bf/EPI_ISL_911536.fasta
11. 1. Pandey R
    2. Kanakan A
    3. Janani SV
    4. Maurya R
    5. Murali AS
    6. Sahni S
    7. Khan A
    8. Chattopadhyay P
    9. Devi P
    10. Mehta P
    11. Kumar A
    12. Rawat N

    (2021) GISAID

    ID EPI_ISL_911547. SARS CoV-2 sequencing data.

    https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_22_qw71ju_3qf46ce08f1f/EPI_ISL_911547.fasta
12. 1. Pandey R
    2. Kanakan A
    3. Janani SV
    4. Maurya R
    5. Murali AS
    6. Sahni S
    7. Khan A
    8. Chattopadhyay P
    9. Devi P
    10. Mehta P
    11. Kumar A
    12. Rawat N

    (2021) GISAID

    ID EPI_ISL_911537. SARS CoV-2 sequencing data.

    https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_23_qw71ju_3qim6ce08e89/EPI_ISL_911537.fasta
13. 1. Pandey R
    2. Kanakan A
    3. Janani SV
    4. Maurya R
    5. Murali AS
    6. Sahni S
    7. Khan A
    8. Chattopadhyay P
    9. Devi P
    10. Mehta P
    11. Kumar A
    12. Rawat N

    (2021) GISAID

    ID EPI_ISL_911538. SARS CoV-2 sequencing data.

    https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_24_qw71ju_3qlo6ce08e2a/EPI_ISL_911538.fasta
14. 1. Pandey R
    2. Kanakan A
    3. Janani SV
    4. Maurya R
    5. Murali AS
    6. Sahni S
    7. Khan A
    8. Chattopadhyay P
    9. Devi P
    10. Mehta P
    11. Kumar A
    12. Rawat N

    (2021) GISAID

    ID EPI_ISL_911540. SARS CoV-2 sequencing data.

    https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_25_qw71ju_3qs16ce08d8f/EPI_ISL_911540.fasta
15. 1. Pandey R
    2. Kanakan A
    3. Janani SV
    4. Maurya R
    5. Murali AS
    6. Sahni S
    7. Khan A
    8. Chattopadhyay P
    9. Devi P
    10. Mehta P
    11. Kumar A
    12. Rawat N

    (2021) GISAID

    ID EPI_ISL_911541. SARS CoV-2 sequencing data.

    https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_26_qw71ju_3qu36ce08d4f/EPI_ISL_911541.fasta
16. 1. Pandey R
    2. Kanakan A
    3. Janani SV
    4. Maurya R
    5. Murali AS
    6. Sahni S
    7. Khan A
    8. Chattopadhyay P
    9. Devi P
    10. Mehta P
    11. Kumar A
    12. Rawat N

    (2021) GISAID

    ID EPI_ISL_911539. SARS CoV-2 sequencing data.

    https://www.epicov.org/epi3/entities/tmp/tmp_sd_2021_07_14_23_26_qw71ju_3qx16ce08cf4/EPI_ISL_911539.fasta

1. 1. Acharya S
   2. Mishra A
   3. Paul D
   4. Ansari AH
   5. Azhar M
   6. Kumar M
   7. Rauthan R
   8. Sharma N
   9. Aich M
   10. Sinha D
   11. Sharma S
   12. Jain S
   13. Ray A
   14. Jain S
   15. Ramalingam S
   16. Maiti S
   17. Chakraborty D

   (2019) Francisella novicida Cas9 interrogates genomic DNA with very high specificity and can be used for mammalian genome editing

   PNAS 116:20959–20968.

   https://doi.org/10.1073/pnas.1818461116

   • PubMed
   • Google Scholar
2. 1. Afzal A

   (2020) Molecular diagnostic technologies for COVID-19: limitations and challenges

   Journal of Advanced Research 26:149–159.

   https://doi.org/10.1016/j.jare.2020.08.002

   • PubMed
   • Google Scholar
3. Preprint

   1. Annavajhala MK
   2. Mohri H
   3. Wang P
   4. Zucker JE
   5. Sheng Z
   6. Gomez-Simmonds A
   7. Bedford T
   8. Dd H
   9. Uhlemann A-C

   (2021) A novel and expanding SARS-CoV-2 variant, b.1.526, identified in New York

   medRxiv.

   https://doi.org/10.1101/2021.02.23.21252259

   • Google Scholar
4. 1. Azhar M
   2. Phutela R
   3. Kumar M
   4. Ansari AH
   5. Rauthan R
   6. Gulati S
   7. Sharma N
   8. Sinha D
   9. Sharma S
   10. Singh S
   11. Acharya S
   12. Sarkar S
   13. Paul D
   14. Kathpalia P
   15. Aich M
   16. Sehgal P
   17. Ranjan G
   18. Bhoyar RC
   19. Singhal K
   20. Lad H
   21. Patra PK
   22. Makharia G
   23. Chandak GR
   24. Pesala B
   25. Chakraborty D
   26. Maiti S
   27. Indian CoV2 Genomics & Genetic Epidemiology (IndiCovGEN) Consortium

   (2021) Rapid and accurate nucleobase detection using FnCas9 and its application in COVID-19 diagnosis

   Biosensors and Bioelectronics 183:113207.

   https://doi.org/10.1016/j.bios.2021.113207

   • PubMed
   • Google Scholar
5. 1. Bhoyar RC
   2. Jain A
   3. Sehgal P
   4. Divakar MK
   5. Sharma D
   6. Imran M
   7. Jolly B
   8. Ranjan G
   9. Rophina M
   10. Sharma S
   11. Siwach S
   12. Pandhare K
   13. Sahoo S
   14. Sahoo M
   15. Nayak A
   16. Mohanty JN
   17. Das J
   18. Bhandari S
   19. Mathur SK
   20. Kumar A
   21. Sahlot R
   22. Rojarani P
   23. Lakshmi JV
   24. Surekha A
   25. Sekhar PC
   26. Mahajan S
   27. Masih S
   28. Singh P
   29. Kumar V
   30. Jose B
   31. Mahajan V
   32. Gupta V
   33. Gupta R
   34. Arumugam P
   35. Singh A
   36. Nandy A
   37. P. V. R
   38. Jha RM
   39. Kumari A
   40. Gandotra S
   41. Rao V
   42. Faruq M
   43. Kumar S
   44. Reshma G B
   45. Varma G N
   46. Roy SS
   47. Sengupta A
   48. Chattopadhyay S
   49. Singhal K
   50. Pradhan S
   51. Jha D
   52. Naushin S
   53. Wadhwa S
   54. Tyagi N
   55. Poojary M
   56. Scaria V
   57. Sivasubbu S

   (2021) High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencing

   PLOS ONE 16:e0247115.

   https://doi.org/10.1371/journal.pone.0247115

   • PubMed
   • Google Scholar
6. 1. Brister JR
   2. Ako-adjei D
   3. Bao Y
   4. Blinkova O

   (2015) NCBI viral genomes resource

   Nucleic Acids Research 43:D571–D577.

   https://doi.org/10.1093/nar/gku1207

   • Google Scholar
7. 1. Broughton JP
   2. Deng X
   3. Yu G
   4. Fasching CL
   5. Servellita V
   6. Singh J
   7. Miao X
   8. Streithorst JA
   9. Granados A
   10. Sotomayor-Gonzalez A
   11. Zorn K
   12. Gopez A
   13. Hsu E
   14. Gu W
   15. Miller S
   16. Pan CY
   17. Guevara H
   18. Wadford DA
   19. Chen JS
   20. Chiu CY

   (2020) CRISPR-Cas12-based detection of SARS-CoV-2

   Nature Biotechnology 38:870–874.

   https://doi.org/10.1038/s41587-020-0513-4

   • PubMed
   • Google Scholar
8. 1. Carter LJ
   2. Garner LV
   3. Smoot JW
   4. Li Y
   5. Zhou Q
   6. Saveson CJ
   7. Sasso JM
   8. Gregg AC
   9. Soares DJ
   10. Beskid TR
   11. Jervey SR
   12. Liu C

   (2020) Assay techniques and test development for COVID-19 diagnosis

   ACS Central Science 6:591–605.

   https://doi.org/10.1021/acscentsci.0c00501

   • PubMed
   • Google Scholar
9. Report

   1. CDC

   (2021) Centers for Disease Control and Prevention

   Health and Human Services.

   https://www.cdc.gov/

   • Google Scholar
10. Report

    1. Chand M

    (2020) Investigation of Novel SARS-COV-2 Variant: Variant of Concern 202012/01

    Public Heal England PHE.

    https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201

    • Google Scholar
11. Preprint

    1. Cheng MH
    2. Krieger JM
    3. Kaynak B
    4. Arditi MA
    5. Bahar I

    (2021) Impact of south african 501. V2 variant on SARS-CoV-2 spike infectivity and neutralization: a structure-based computational assessment

    bioRxiv.

    https://doi.org/10.1101/2021.01.10.426143

    • Google Scholar
12. 1. Chiu CY
    2. Miller SA

    (2019) Clinical metagenomics

    Nature Reviews Genetics 20:341–355.

    https://doi.org/10.1038/s41576-019-0113-7

    • PubMed
    • Google Scholar
13. 1. Collier DA
    2. De Marco A
    3. Ferreira I
    4. Meng B
    5. Datir RP
    6. Walls AC
    7. Kemp SA
    8. Bassi J
    9. Pinto D
    10. Silacci-Fregni C
    11. Bianchi S
    12. Tortorici MA
    13. Bowen J
    14. Culap K
    15. Jaconi S
    16. Cameroni E
    17. Snell G
    18. Pizzuto MS
    19. Pellanda AF
    20. Garzoni C
    21. Riva A
    22. Elmer A
    23. Kingston N
    24. Graves B
    25. McCoy LE
    26. Smith KGC
    27. Bradley JR
    28. Temperton N
    29. Ceron-Gutierrez L
    30. Barcenas-Morales G
    31. Harvey W
    32. Virgin HW
    33. Lanzavecchia A
    34. Piccoli L
    35. Doffinger R
    36. Wills M
    37. Veesler D
    38. Corti D
    39. Gupta RK
    40. CITIID-NIHR BioResource COVID-19 Collaboration
    41. COVID-19 Genomics UK (COG-UK) Consortium

    (2021) Sensitivity of SARS-CoV-2 b.1.1.7 to mRNA vaccine-elicited antibodies

    Nature 593:136–141.

    https://doi.org/10.1038/s41586-021-03412-7

    • PubMed
    • Google Scholar
14. 1. Davies NG
    2. Abbott S
    3. Barnard RC
    4. Jarvis CI
    5. Kucharski AJ
    6. Munday JD
    7. Pearson CAB
    8. Russell TW
    9. Tully DC
    10. Washburne AD
    11. Wenseleers T
    12. Gimma A
    13. Waites W
    14. Wong KLM
    15. van Zandvoort K
    16. Silverman JD
    17. Diaz-Ordaz K
    18. Keogh R
    19. Eggo RM
    20. Funk S
    21. Jit M
    22. Atkins KE
    23. Edmunds WJ
    24. CMMID COVID-19 Working Group
    25. COVID-19 Genomics UK (COG-UK) Consortium

    (2021) Estimated transmissibility and impact of SARS-CoV-2 lineage b.1.1.7 in England

    Science 372:eabg3055.

    https://doi.org/10.1126/science.abg3055

    • PubMed
    • Google Scholar
15. 1. Dejnirattisai W
    2. Zhou D
    3. Supasa P
    4. Liu C
    5. Mentzer AJ
    6. Ginn HM
    7. Zhao Y
    8. Duyvesteyn HME
    9. Tuekprakhon A
    10. Nutalai R
    11. Wang B
    12. López-Camacho C
    13. Slon-Campos J
    14. Walter TS
    15. Skelly D
    16. Costa Clemens SA
    17. Naveca FG
    18. Nascimento V
    19. Nascimento F
    20. Fernandes da Costa C
    21. Resende PC
    22. Pauvolid-Correa A
    23. Siqueira MM
    24. Dold C
    25. Levin R
    26. Dong T
    27. Pollard AJ
    28. Knight JC
    29. Crook D
    30. Lambe T
    31. Clutterbuck E
    32. Bibi S
    33. Flaxman A
    34. Bittaye M
    35. Belij-Rammerstorfer S
    36. Gilbert SC
    37. Carroll MW
    38. Klenerman P
    39. Barnes E
    40. Dunachie SJ
    41. Paterson NG
    42. Williams MA
    43. Hall DR
    44. Hulswit RJG
    45. Bowden TA
    46. Fry EE
    47. Mongkolsapaya J
    48. Ren J
    49. Stuart DI
    50. Screaton GR

    (2021) Antibody evasion by the p.1 strain of SARS-CoV-2

    Cell 184:2939–2954.

    https://doi.org/10.1016/j.cell.2021.03.055

    • PubMed
    • Google Scholar
16. 1. Ding X
    2. Yin K
    3. Li Z
    4. Lalla RV
    5. Ballesteros E
    6. Sfeir MM
    7. Liu C

    (2020) Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay

    Nature Communications 11:1–10.

    https://doi.org/10.1038/s41467-020-18575-6

    • Google Scholar
17. 1. Faria NR
    2. Claro IM
    3. Candido D
    4. Moyses Franco LA
    5. Andrade PS
    6. Coletti TM
    7. Silva CAM
    8. Sales FC
    9. Manuli ER
    10. Aguiar RS

    (2021) Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

    Virological 372:815–821.

    https://doi.org/10.1126/science.abh2644

    • Google Scholar
18. 1. Fontanet A
    2. Autran B
    3. Lina B
    4. Kieny MP
    5. Karim SSA
    6. Sridhar D

    (2021) SARS-CoV-2 variants and ending the COVID-19 pandemic

    The Lancet 397:952–954.

    https://doi.org/10.1016/S0140-6736(21)00370-6

    • Google Scholar
19. 1. Fozouni P
    2. Son S
    3. Díaz de León Derby M
    4. Knott GJ
    5. Gray CN
    6. D'Ambrosio MV
    7. Zhao C
    8. Switz NA
    9. Kumar GR
    10. Stephens SI
    11. Boehm D
    12. Tsou CL
    13. Shu J
    14. Bhuiya A
    15. Armstrong M
    16. Harris AR
    17. Chen PY
    18. Osterloh JM
    19. Meyer-Franke A
    20. Joehnk B
    21. Walcott K
    22. Sil A
    23. Langelier C
    24. Pollard KS
    25. Crawford ED
    26. Puschnik AS
    27. Phelps M
    28. Kistler A
    29. DeRisi JL
    30. Doudna JA
    31. Fletcher DA
    32. Ott M

    (2021) Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy

    Cell 184:323–333.

    https://doi.org/10.1016/j.cell.2020.12.001

    • PubMed
    • Google Scholar
20. 1. Frankish A
    2. Diekhans M
    3. Ferreira AM
    4. Johnson R
    5. Jungreis I
    6. Loveland J
    7. Mudge JM
    8. Sisu C
    9. Wright J
    10. Armstrong J
    11. Barnes I
    12. Berry A
    13. Bignell A
    14. Carbonell Sala S
    15. Chrast J
    16. Cunningham F
    17. Di Domenico T
    18. Donaldson S
    19. Fiddes IT
    20. García Girón C
    21. Gonzalez JM
    22. Grego T
    23. Hardy M
    24. Hourlier T
    25. Hunt T
    26. Izuogu OG
    27. Lagarde J
    28. Martin FJ
    29. Martínez L
    30. Mohanan S
    31. Muir P
    32. Navarro FCP
    33. Parker A
    34. Pei B
    35. Pozo F
    36. Ruffier M
    37. Schmitt BM
    38. Stapleton E
    39. Suner MM
    40. Sycheva I
    41. Uszczynska-Ratajczak B
    42. Xu J
    43. Yates A
    44. Zerbino D
    45. Zhang Y
    46. Aken B
    47. Choudhary JS
    48. Gerstein M
    49. Guigó R
    50. Hubbard TJP
    51. Kellis M
    52. Paten B
    53. Reymond A
    54. Tress ML
    55. Flicek P

    (2019) GENCODE reference annotation for the human and mouse genomes

    Nucleic Acids Research 47:D766–D773.

    https://doi.org/10.1093/nar/gky955

    • PubMed
    • Google Scholar
21. 1. Guo L
    2. Sun X
    3. Wang X
    4. Liang C
    5. Jiang H
    6. Gao Q
    7. Dai M
    8. Qu B
    9. Fang S
    10. Mao Y
    11. Chen Y
    12. Feng G
    13. Gu Q
    14. Wang RR
    15. Zhou Q
    16. Li W

    (2020) SARS-CoV-2 detection with CRISPR diagnostics

    Cell Discovery 6:1–4.

    https://doi.org/10.1038/s41421-020-0174-y

    • PubMed
    • Google Scholar
22. 1. Hadfield J
    2. Megill C
    3. Bell SM
    4. Huddleston J
    5. Potter B
    6. Callender C
    7. Sagulenko P
    8. Bedford T
    9. Neher RA

    (2018) Nextstrain: real-time tracking of pathogen evolution

    Bioinformatics 34:4121–4123.

    https://doi.org/10.1093/bioinformatics/bty407

    • PubMed
    • Google Scholar
23. Software

    1. Horby P
    2. Huntley C
    3. Davies N
    4. Edmunds J
    5. Ferguson N
    6. Medley G
    7. Semple C

    (2021) NERVTAG note on B. 1.1. 7 severity, version 1.1.7

    NERVTAG.

    https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961037/NERVTAG_note_on_B.1.1.7_severity_for_SAGE_77__1_.pdf
24. 1. Jayamohan H
    2. Lambert CJ
    3. Sant HJ
    4. Jafek A
    5. Patel D
    6. Feng H
    7. Beeman M
    8. Mahmood T
    9. Nze U
    10. Gale BK

    (2021) SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations

    Analytical and Bioanalytical Chemistry 413:49–71.

    https://doi.org/10.1007/s00216-020-02958-1

    • PubMed
    • Google Scholar
25. 1. Joung J
    2. Ladha A
    3. Saito M
    4. Kim N-G
    5. Woolley AE
    6. Segel M
    7. Barretto RPJ
    8. Ranu A
    9. Macrae RK
    10. Faure G
    11. Ioannidi EI
    12. Krajeski RN
    13. Bruneau R
    14. Huang M-LW
    15. Yu XG
    16. Li JZ
    17. Walker BD
    18. Hung DT
    19. Greninger AL
    20. Jerome KR
    21. Gootenberg JS
    22. Abudayyeh OO
    23. Zhang F

    (2020) Detection of SARS-CoV-2 with SHERLOCK One-Pot testing

    New England Journal of Medicine 383:1492–1494.

    https://doi.org/10.1056/NEJMc2026172

    • Google Scholar
26. 1. Klempt P
    2. Brož P
    3. Kašný M
    4. Novotný A
    5. Kvapilová K
    6. Kvapil P

    (2020) Performance of targeted library preparation solutions for SARS-CoV-2 whole genome analysis

    Diagnostics 10:769.

    https://doi.org/10.3390/diagnostics10100769

    • Google Scholar
27. 1. Korber B
    2. Fischer WM
    3. Gnanakaran S
    4. Yoon H
    5. Theiler J
    6. Abfalterer W
    7. Hengartner N
    8. Giorgi EE
    9. Bhattacharya T
    10. Foley B
    11. Hastie KM
    12. Parker MD
    13. Partridge DG
    14. Evans CM
    15. Freeman TM
    16. de Silva TI
    17. McDanal C
    18. Perez LG
    19. Tang H
    20. Moon-Walker A
    21. Whelan SP
    22. LaBranche CC
    23. Saphire EO
    24. Montefiori DC
    25. Sheffield COVID-19 Genomics Group

    (2020) Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

    Cell 182:812–827.

    https://doi.org/10.1016/j.cell.2020.06.043

    • PubMed
    • Google Scholar
28. 1. Ku Z
    2. Xie X
    3. Davidson E
    4. Ye X
    5. Su H
    6. Menachery VD
    7. Li Y
    8. Yuan Z
    9. Zhang X
    10. Muruato AE
    11. I Escuer AG
    12. Tyrell B
    13. Doolan K
    14. Doranz BJ
    15. Wrapp D
    16. Bates PF
    17. McLellan JS
    18. Weiss SR
    19. Zhang N
    20. Shi PY
    21. An Z

    (2021) Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape

    Nature Communications 12:469.

    https://doi.org/10.1038/s41467-020-20789-7

    • PubMed
    • Google Scholar
29. 1. Li H

    (2018) Minimap2: pairwise alignment for nucleotide sequences

    Bioinformatics 34:3094–3100.

    https://doi.org/10.1093/bioinformatics/bty191

    • PubMed
    • Google Scholar
30. 1. Little S

    (2001) Amplification-refractory mutation system (ARMS) analysis of point mutations

    Current Protocols in Human Genetics 8:9.

    https://doi.org/10.1002/0471142905.hg0908s07

    • Google Scholar
31. 1. Loman NJ
    2. Quick J
    3. Simpson JT

    (2015) A complete bacterial genome assembled de novo using only nanopore sequencing data

    Nature Methods 12:733–735.

    https://doi.org/10.1038/nmeth.3444

    • PubMed
    • Google Scholar
32. Preprint

    1. Luan B
    2. Wang H
    3. Huynh T

    (2021) Molecular mechanism of the N501Y mutation for enhanced binding between SARS-CoV-2’s Spike Protein and Human ACE2 Receptor

    bioRxiv.

    https://doi.org/10.1101/2021.01.04.425316

    • Google Scholar
33. Preprint

    1. Lucia C
    2. Federico P-B
    3. Alejandra GC

    (2020) An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12

    bioRxiv.

    https://doi.org/10.1101/2020.02.29.971127

    • Google Scholar
34. 1. Mackay IM

    (2002) Real-time PCR in virology

    Nucleic Acids Research 30:1292–1305.

    https://doi.org/10.1093/nar/30.6.1292

    • Google Scholar
35. 1. McNamara RP
    2. Caro-Vegas C
    3. Landis JT
    4. Moorad R
    5. Pluta LJ
    6. Eason AB
    7. Thompson C
    8. Bailey A
    9. Villamor FCS
    10. Lange PT
    11. Wong JP
    12. Seltzer T
    13. Seltzer J
    14. Zhou Y
    15. Vahrson W
    16. Juarez A
    17. Meyo JO
    18. Calabre T
    19. Broussard G
    20. Rivera-Soto R
    21. Chappell DL
    22. Baric RS
    23. Damania B
    24. Miller MB
    25. Dittmer DP

    (2020) High-Density amplicon sequencing identifies community spread and ongoing evolution of SARS-CoV-2 in the southern united states

    Cell Reports 33:108352.

    https://doi.org/10.1016/j.celrep.2020.108352

    • PubMed
    • Google Scholar
36. 1. Meredith LW
    2. Hamilton WL
    3. Warne B
    4. Houldcroft CJ
    5. Hosmillo M
    6. Jahun AS
    7. Curran MD
    8. Parmar S
    9. Caller LG
    10. Caddy SL
    11. Khokhar FA
    12. Yakovleva A
    13. Hall G
    14. Feltwell T
    15. Forrest S
    16. Sridhar S
    17. Weekes MP
    18. Baker S
    19. Brown N
    20. Moore E
    21. Popay A
    22. Roddick I
    23. Reacher M
    24. Gouliouris T
    25. Peacock SJ
    26. Dougan G
    27. Török ME
    28. Goodfellow I

    (2020) Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study

    The Lancet Infectious Diseases 20:1263–1271.

    https://doi.org/10.1016/S1473-3099(20)30562-4

    • PubMed
    • Google Scholar
37. 1. Naveca F
    2. da Costa C
    3. Nascimento V
    4. Souza V
    5. Corado A
    6. Nascimento F
    7. Á C
    8. Duarte D
    9. Silva G
    10. Mejía M

    (2021) SARS-CoV-2 reinfection by the new variant of concern (VOC) P. 1 in Amazonas, Brazil

    Virolorgy 10:318392.

    https://doi.org/10.21203/rs.3.rs-318392/v1

    • Google Scholar
38. 1. Nonaka CKV
    2. Franco MM
    3. Gräf T
    4. de Lorenzo Barcia CA
    5. de Ávila Mendonça RN
    6. de Sousa KAF
    7. Neiva LMC
    8. Fosenca V
    9. Mendes AVA
    10. de Aguiar RS
    11. Giovanetti M
    12. de Freitas Souza BS

    (2021) Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil

    Emerging Infectious Diseases 27:1522–1524.

    https://doi.org/10.3201/eid2705.210191

    • PubMed
    • Google Scholar
39. 1. Oude Munnink BB
    2. Nieuwenhuijse DF
    3. Stein M
    4. O'Toole Á
    5. Haverkate M
    6. Mollers M
    7. Kamga SK
    8. Schapendonk C
    9. Pronk M
    10. Lexmond P
    11. van der Linden A
    12. Bestebroer T
    13. Chestakova I
    14. Overmars RJ
    15. van Nieuwkoop S
    16. Molenkamp R
    17. van der Eijk AA
    18. GeurtsvanKessel C
    19. Vennema H
    20. Meijer A
    21. Rambaut A
    22. van Dissel J
    23. Sikkema RS
    24. Timen A
    25. Koopmans M
    26. Dutch-Covid-19 response team

    (2020) Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the netherlands

    Nature Medicine 26:1405–1410.

    https://doi.org/10.1038/s41591-020-0997-y

    • PubMed
    • Google Scholar
40. 1. Pachetti M
    2. Marini B
    3. Benedetti F
    4. Giudici F
    5. Mauro E
    6. Storici P
    7. Masciovecchio C
    8. Angeletti S
    9. Ciccozzi M
    10. Gallo RC
    11. Zella D
    12. Ippodrino R

    (2020) Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

    Journal of Translational Medicine 18:179.

    https://doi.org/10.1186/s12967-020-02344-6

    • PubMed
    • Google Scholar
41. 1. Patchsung M
    2. Jantarug K
    3. Pattama A
    4. Aphicho K
    5. Suraritdechachai S
    6. Meesawat P
    7. Sappakhaw K
    8. Leelahakorn N
    9. Ruenkam T
    10. Wongsatit T
    11. Athipanyasilp N
    12. Eiamthong B
    13. Lakkanasirorat B
    14. Phoodokmai T
    15. Niljianskul N
    16. Pakotiprapha D
    17. Chanarat S
    18. Homchan A
    19. Tinikul R
    20. Kamutira P
    21. Phiwkaow K
    22. Soithongcharoen S
    23. Kantiwiriyawanitch C
    24. Pongsupasa V
    25. Trisrivirat D
    26. Jaroensuk J
    27. Wongnate T
    28. Maenpuen S
    29. Chaiyen P
    30. Kamnerdnakta S
    31. Swangsri J
    32. Chuthapisith S
    33. Sirivatanauksorn Y
    34. Chaimayo C
    35. Sutthent R
    36. Kantakamalakul W
    37. Joung J
    38. Ladha A
    39. Jin X
    40. Gootenberg JS
    41. Abudayyeh OO
    42. Zhang F
    43. Horthongkham N
    44. Uttamapinant C

    (2020) Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA

    Nature Biomedical Engineering 4:1140–1149.

    https://doi.org/10.1038/s41551-020-00603-x

    • PubMed
    • Google Scholar
42. 1. Rabi FA
    2. Al Zoubi MS
    3. Kasasbeh GA
    4. Salameh DM
    5. Al-Nasser AD

    (2020) SARS-CoV-2 and coronavirus disease 2019: what we know so far

    Pathogens 9:231.

    https://doi.org/10.3390/pathogens9030231

    • Google Scholar
43. 1. Rambaut A
    2. Holmes EC
    3. O'Toole Á
    4. Hill V
    5. McCrone JT
    6. Ruis C
    7. du Plessis L
    8. Pybus OG

    (2020) A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

    Nature Microbiology 5:1403–1407.

    https://doi.org/10.1038/s41564-020-0770-5

    • PubMed
    • Google Scholar
44. 1. Resende PC
    2. Bezerra JF
    3. Rht V
    4. Arantes I
    5. Appolinario L
    6. Mendonça AC
    7. Paixao AC
    8. Rodrigues ACD
    9. Silva T
    10. Rocha AS

    (2021)

    Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020

    Virol 10:2020.

    • Google Scholar
45. 1. Rockett RJ
    2. Arnott A
    3. Lam C
    4. Sadsad R
    5. Timms V
    6. Gray KA
    7. Eden JS
    8. Chang S
    9. Gall M
    10. Draper J
    11. Sim EM
    12. Bachmann NL
    13. Carter I
    14. Basile K
    15. Byun R
    16. O'Sullivan MV
    17. Chen SC
    18. Maddocks S
    19. Sorrell TC
    20. Dwyer DE
    21. Holmes EC
    22. Kok J
    23. Prokopenko M
    24. Sintchenko V

    (2020) Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling

    Nature Medicine 26:1398–1404.

    https://doi.org/10.1038/s41591-020-1000-7

    • PubMed
    • Google Scholar
46. 1. Shu Y
    2. McCauley J

    (2017) GISAID: global initiative on sharing all influenza data - from vision to reality

    Eurosurveillance 22:30494.

    https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494

    • PubMed
    • Google Scholar
47. Preprint

    1. Tegally H
    2. Wilkinson E
    3. Giovanetti M
    4. Iranzadeh A
    5. Fonseca V
    6. Giandhari J
    7. Doolabh D
    8. Pillay S
    9. San EJ
    10. Msomi N

    (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

    medRxiv.

    https://doi.org/10.1101/2020.12.21.20248640

    • Google Scholar
48. Preprint

    1. Tian F
    2. Tong B
    3. Sun L
    4. Shi S
    5. Zheng B
    6. Wang Z
    7. Dong X
    8. Zheng P

    (2021) Mutation N501Y in RBD of spike protein strengthens the interaction between COVID-19 and its receptor ACE2

    bioRxiv.

    https://doi.org/10.1101/2021.02.14.431117

    • Google Scholar
49. 1. Untergasser A
    2. Cutcutache I
    3. Koressaar T
    4. Ye J
    5. Faircloth BC
    6. Remm M
    7. Rozen SG

    (2012) Primer3--new capabilities and interfaces

    Nucleic Acids Research 40:e115.

    https://doi.org/10.1093/nar/gks596

    • PubMed
    • Google Scholar
50. 1. Vandenberg O
    2. Martiny D
    3. Rochas O
    4. van Belkum A
    5. Kozlakidis Z

    (2021) Considerations for diagnostic COVID-19 tests

    Nature Reviews Microbiology 19:171–183.

    https://doi.org/10.1038/s41579-020-00461-z

    • Google Scholar
51. 1. Volz E
    2. Mishra S
    3. Chand M
    4. Barrett JC
    5. Johnson R
    6. Geidelberg L
    7. Hinsley WR
    8. Laydon DJ
    9. Dabrera G
    10. O'Toole Á
    11. Amato R
    12. Ragonnet-Cronin M
    13. Harrison I
    14. Jackson B
    15. Ariani CV
    16. Boyd O
    17. Loman NJ
    18. McCrone JT
    19. Gonçalves S
    20. Jorgensen D
    21. Myers R
    22. Hill V
    23. Jackson DK
    24. Gaythorpe K
    25. Groves N
    26. Sillitoe J
    27. Kwiatkowski DP
    28. Flaxman S
    29. Ratmann O
    30. Bhatt S
    31. Hopkins S
    32. Gandy A
    33. Rambaut A
    34. Ferguson NM
    35. COVID-19 Genomics UK (COG-UK) consortium

    (2021) Assessing transmissibility of SARS-CoV-2 lineage b.1.1.7 in England

    Nature 593:266–269.

    https://doi.org/10.1038/s41586-021-03470-x

    • PubMed
    • Google Scholar
52. 1. Walensky RP
    2. Walke HT
    3. Fauci AS

    (2021) SARS-CoV-2 variants of concern in the united States-Challenges and opportunities

    Jama 325:1037–1038.

    https://doi.org/10.1001/jama.2021.2294

    • PubMed
    • Google Scholar
53. 1. Wang R
    2. Qian C
    3. Pang Y
    4. Li M
    5. Yang Y
    6. Ma H
    7. Zhao M
    8. Qian F
    9. Yu H
    10. Liu Z
    11. Ni T
    12. Zheng Y
    13. Wang Y

    (2021) opvCRISPR: one-pot visual RT-LAMP-CRISPR platform for SARS-cov-2 detection

    Biosensors and Bioelectronics 172:112766.

    https://doi.org/10.1016/j.bios.2020.112766

    • PubMed
    • Google Scholar
54. 1. Weisblum Y
    2. Schmidt F
    3. Zhang F
    4. DaSilva J
    5. Poston D
    6. Lorenzi JC
    7. Muecksch F
    8. Rutkowska M
    9. Hoffmann HH
    10. Michailidis E
    11. Gaebler C
    12. Agudelo M
    13. Cho A
    14. Wang Z
    15. Gazumyan A
    16. Cipolla M
    17. Luchsinger L
    18. Hillyer CD
    19. Caskey M
    20. Robbiani DF
    21. Rice CM
    22. Nussenzweig MC
    23. Hatziioannou T
    24. Bieniasz PD

    (2020) Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

    eLife 9:e61312.

    https://doi.org/10.7554/eLife.61312

    • PubMed
    • Google Scholar
55. 1. Wibmer CK
    2. Ayres F
    3. Hermanus T
    4. Madzivhandila M
    5. Kgagudi P
    6. Oosthuysen B
    7. Lambson BE
    8. de Oliveira T
    9. Vermeulen M
    10. van der Berg K
    11. Rossouw T
    12. Boswell M
    13. Ueckermann V
    14. Meiring S
    15. von Gottberg A
    16. Cohen C
    17. Morris L
    18. Bhiman JN
    19. Moore PL

    (2021) SARS-CoV-2 501Y.V2 escapes neutralization by south african COVID-19 donor plasma

    Nature Medicine 27:622–625.

    https://doi.org/10.1038/s41591-021-01285-x

    • PubMed
    • Google Scholar
56. 1. Xie X
    2. Liu Y
    3. Liu J
    4. Zhang X
    5. Zou J
    6. Fontes-Garfias CR
    7. Xia H
    8. Swanson KA
    9. Cutler M
    10. Cooper D
    11. Menachery VD
    12. Weaver SC
    13. Dormitzer PR
    14. Shi PY

    (2021) Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

    Nature Medicine 27:620–621.

    https://doi.org/10.1038/s41591-021-01270-4

    • PubMed
    • Google Scholar
57. 1. Yin C

    (2020) Genotyping coronavirus SARS-CoV-2: methods and implications

    Genomics 112:3588–3596.

    https://doi.org/10.1016/j.ygeno.2020.04.016

    • PubMed
    • Google Scholar
58. 1. Zhou B
    2. Thao TTN
    3. Hoffmann D
    4. Taddeo A
    5. Ebert N
    6. Labroussaa F
    7. Pohlmann A
    8. King J
    9. Steiner S
    10. Kelly JN
    11. Portmann J
    12. Halwe NJ
    13. Ulrich L
    14. Trüeb BS
    15. Fan X
    16. Hoffmann B
    17. Wang L
    18. Thomann L
    19. Lin X
    20. Stalder H
    21. Pozzi B
    22. de Brot S
    23. Jiang N
    24. Cui D
    25. Hossain J
    26. Wilson MM
    27. Keller MW
    28. Stark TJ
    29. Barnes JR
    30. Dijkman R
    31. Jores J
    32. Benarafa C
    33. Wentworth DE
    34. Thiel V
    35. Beer M

    (2021) SARS-CoV-2 spike D614G change enhances replication and transmission

    Nature 592:122–127.

    https://doi.org/10.1038/s41586-021-03361-1

    • PubMed
    • Google Scholar

Acceptance summary:

This paper is likely to be of interest to those interested in developing diagnostic tools for rapid low cost detection of single nucleotide variants in viral and host pathogenic sequences; genetic disorders and development of precision medicine. Although the key scientific claims are an extension to a recently developed CRISPR diagnostic platform by the same group, this advance has potential application to the COVID-19 pandemic.

The manuscript was revised to provide data and detailed methodologies to support the detection of two major variants of SARs CoV-2. It has been re-written such that the reader need not be familiar with the previous methodology published by the authors, which has been extended to detect these variants.

Decision letter after peer review:

Thank you for submitting your work entitled "RAY: CRISPR diagnostic for rapid and accurate detection of SARS-CoV-2 variants on a paper strip" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and K VijayRaghavan as the Senior Editor.

The manuscript has some issues that need to be addressed, as outlined below:

This paper will be of interest to scientists interested in developing diagnostic tools for rapid low cost detection of SNVs in viral and host pathogenic sequences; genetic disorders and development of precision medicine. Although this tool has immediate application in healthcare during the current pandemic, the key scientific claims of the manuscript are an extension to a recently developed CRISPR diagnostic platform by the same groups. Further data and detailed methodologies need to be provided to support generalizing of the conclusions for applications to a broader field beyond detection of the two 2 variants of SARs-CoV-2.

Briefly, we request a revised manuscript. It is written such that the reader must already be familiar with a previous paper published by the authors, of which this is an extension to detect variants. The manuscript should be stand alone and include all information about this assay and the method validation result. As the title of this manuscript is "detection of variants on a paper strip", generalizability must be addressed if this assay is able to do that. If not, the authors must discuss how to achieve generality and revise the title to "detection of common SARS-CoV-2 variants". In this scenario, the results can support the title.

Reviewer 1:

Researchers from different groups have employed CRISPR-Cas9 protein variants (Cas13, and Cas12a) to develop nucleic acids detection platforms such as SHERLOCK (2017, Science, 356, 438; 2018, Science, 360, 439) and DETECTR (2018, Science, 360, 436). Both SHERLOCK and DETECTR rely on the "collateral effect" – promiscuous cleavage and degradation of neighboring ssRNA and ssDNA by Cas13 and Cas12a. Upon target binding, it will cleave the ssDNA probe. These CRISPR-based detections were used for SARS-CoV-2 detection after then (2020, Nature Biotechnology, 38, 870).

Authors previously reported that Francisella novicida (FnCas9) could be used for gene editing. In authors' preprint project, they reported the high specificity of FnCas9 to the point mismatch at the specific position of gRNA and there is no "collateral effect" of FnCas9. Based on this discovery, they developed a non-cleavage, affinity-based method for the nucleobase detection with single nucleotide mismatch sensitivity (ref 25).

Authors leverage the single nucleotide mismatch sensitivity of FnCAS9 and report herein a non-cleavage, affinity-based SARS-CoV-2 variants detection.

Strengths:

– This assay provides a simple, rapid way to detect SARS-CoV-2 and its SNV.

– Authors demonstrated the detection of SARS-CoV-2 and SAR-S-CoV2 variants (N501Y) in 18 patient samples and validated the samples by sequencing.

Weaknesses:

– Although authors cite their previous preprint paper (similar assay called "FELUDA"), authors didn't describe any sensing mechanism of this assay (RAY). Readers cannot understand this assay by reading this manuscript only. The lack of description in this manuscript strongly affects readers to understand the experiments. Authors assume readers have read another article from the same group and understand the design and mechanism of their "FELUDA" assay. For example, Authors didn't mention that active FnCas9 was used in the experiment in Figure 2a while catalytic inactive FnCas9 was used for SNV detection assay "RAY".

– Only N501Y detection was demonstrated in this project. Authors did not demonstrate the generalizability of this assay by demonstration of detecting other SARS-CoV-2 variants. Furthermore, authors mentioned that only 10/32 SNV sites were targetable by FnCas9.

– The concept / sensing mechanism of this assay is very similar to the assay reported in the same group (ref 25). They used a lot of results / discovery in the preprint (ref 25) to develop this assay and there are only 4 sets of new data reported in this manuscript.

There are several points that may help authors to improve this project.

"We found that out of the 32 defining SNVs 100 reported across all the three lineages, 10 sites were targetable by FnCas9 (Figure 1B,C, Supplementary Table 1)"

Figure 1B shows the evolution of SARS-CoV-2 virus. How is it related to this statement? Figure 1C shows the position of different mutations in the genome. Why is it important to show the position of the mutations? Is it related to the targetability of FnCas9? Explanation is needed.

Authors should explain how they find 10 of 32 single nucleotide variation (SNV) sites are targetable by FnCas9. Why only 10/32 SNV sites are targetable? Authors should explain this result. Without this explanation, readers will not understand how this assay works and how to use this assay to detect other SNV.

As only 10 of 32 SNV sites are targetable, authors should discuss the generalizability of this assay.

"Thirdly, we made modifications at the level of amplicon length, PCR conditions, and RNP concentration to generate the most optimal protocol that can produce a clear discernible signal on a commercially available paper strip"

No data is shown about PCR conditions and RNP concentration optimization. Why does the assay not work well when the amplicon length is 541 bp or less?

In my view, the combination of the preprint paper (ref 25) and this manuscript will make it a detailed, comprehensive project.

There are additional points that need addressing to improve this paper.

Only N501Y detection was demonstrated in this paper strip assay. Paper strip detection of other targetable SNV sites could show the generalizability of this assay in specific conditions.

This manuscript has a lot of abbreviations, but some of them only appear 1 or 2 times. It makes this manuscript difficult for readers to read.

It is confused that Wt, mut and N501Y are all present in Figure 2a. Authors are suggested to label it more clearly to show that it is WT and mutated sgRNA (N501Y).

"Finally, we tested RAY on RNA extracted from samples of RT-PCR positive SARS-CoV-2 infected individuals who returned to India from the United Kingdom between December 2020 and January 2021."

The travel history of the patient is not necessary for assay validation.

Reviewer 2:

The authors report the development of a CRISPR diagnostic platform for detecting variants (N501Y and T716I) in SARS-CoV-2. This is based on a technology, recently developed by the same research groups, using a Cas9 ortholog from Francisella novicida (FnCas9) based enzymatic readout for detecting nucleotide sequences. RAY (Rapid variant Assay), detect both the infection as well as the presence of the common N501Y mutation present in the 3 new variants and distinguish it from the parent CoV-2 lineage. The authors also adapt RAY to a lateral flow paper strip assay for low-cost rapid detection. This represents a novel sequencing-free rapid detection system for CoV-2 mutations.

Although the paper does have major strengths in principle, the authors have not provided sufficient data and information directly for an end user to adapt this platform to their use. For a stand-alone resource article, authors must provide all the critical information within the text, figures, methods and supplementary figures required to understand the range, specificity, sensitivity, limits and error prone aspects (if any) of the technology.

Further information and clarification are required for the following points:

Primer design and selection:

1. Given that the authors mention that they successfully established that FnCas9 is unable to bind or cleave targets having two mismatches -in the 2nd and 6th position; why were PAMs searched with mismatches in the 16th and 19th position (Figure 1D)?

2. How many pairs of flanking primers need to be designed for a specific point mutation? What experimental output would demonstrate optimal primer design?

3. More details on the amplicons are required.

IVC Detection

1. What size fragments were generated? Was only one sgRNA used for each N501Y and T716I?

In figure 2a it seems like the amount of wild type amplicon is higher or equal to one of the cleaved fragments in the N501Y sample gel (mut lane). Is this due to poor cleavage by the FnCas9? A densitometry analysis would provide better quantification of fragment formations.

2. What is the specificity, selectivity for each of these variants? Do altering sgRNA change the specificity? What conditions are necessary for the reaction to go to completion? How does one account for false negatives; is there a low copy number limit for this detection system. No experimental results have been provided for any of this.

3. For the reaction between FnCas9 and sample/amplicons what are the ratio ranges; concentrations; volumes to be followed?

LFA Detection

1. Please elaborate the protocol for "modified single step" RT-PCR.

2. The authors mention that they eliminate one of the biotin label primers to reduce the chances of background signal due to non-specific interactions of the unused biotin primers with the streptavidin. The authors should compare and quantitate the output using various methods used in the current work as well as previous FELUDA paper [double biotin labels; synthetic phosphothioate modified RNA etc]

3. Authors should explain the difference between FnCas9 and dFnCas9 in at least the methods.

4. What are the limits of detection of RAY? Is it similar to FELUDA? How does changing sgRNA/ chimeric gRNA effect the detection limit? No experimental results have been provided for this.

5. If the only method of detection analysis is TOPSE then the authors must provide more details of how to access/use the app.

Reviewer 3:

The work by Kumar et al. presents a new diagnostic technique (called "RAY") for detecting SARS-CoV-2 virus infection (responsible for the current COVID-19 pandemic). The researchers use a CRISPR-based method to provide a "quick" assay that can distinguish COVID positive and negative samples. This method is an extension of their previous work on a COVID-19 assay called FELUDA (https://www.medrxiv.org/content/10.1101/2020.09.13.20193581v1). The focus of the current work is to specifically identify COVID-positive samples as well as the particular variant of the viral genome. Typically, the different SARS-CoV-2 variants could differ by a few differences in the genome sequence. This work uses the specificity of the CRISPR reaction: the enzymatic cleavage only occurs for a completely complementary target and not for a target with mutations. The authors developed a lateral flow assay, where the signal corresponding to detection of the viral RNA and/or the mutant is read out as a line on a paper strip (similar to pregnancy strips). Appearance of these lines indicate presence of the virus in the sample. The work used 8 COVID positive samples, 8 positive samples with the mutation N501Y (earlier shown to be present in the British, South African and Brazilian variants of SARS-CoV-2), and 12 COVID negative samples, and identified all the clinical samples accurately.

In terms of the scope, the current work demonstrates COVID19 mutation detection with an easy lateral flow-based readout, within ~75 minutes. While the assay has been shown to be able to detect 20 samples accurately, a larger data set might be needed to evaluate the sensitivity of the assay and the range of viral loads it can detect. The past year has seen a number of new techniques for COVID19 diagnosis, all of which will be useful for the still ongoing large-scale testing worldwide. In that context, this assay has practical and immediate use for COVID19 detection if it can be commercialized, especially with the rise of a number of variants of the SARS-CoV-2 virus.

I liked reading the paper – it was very clear and crisp, and the data was well presented in both the text and the figures. However, as written, the paper seems to rely heavily on the reader's knowledge of their earlier work on FELUDA. From a reader's point of view, I felt that certain aspects of the assay, methodology and scope of immediate use could be expanded here even if it is a repeat from the authors' FELUDA work, to make this a stand-alone paper.

Discussion can be included on the following points. While these are not technical concerns, I think it will be informative for scientific and lay audience to know where the assay stands in terms of immediate impact for COVID19 pandemic.

– Metrics of the assay such as sensitivity and specificity (even if referring to previous works).

– Scope of the assay: Do the authors intend to use this as a clinical test or at POC? Specific aspects can be discussed for either or both of these scenarios.

– For the assay to be useful in POC setting, sample processing is an important step. Assuming samples are collected on swabs, RNA needs to be extracted before RAY can be performed. How can this be brought into the regular workflow for the assay to work at a testing site outside a lab or clinical facility? How will this affect the cost of the assay? The tally of the assay cost excludes RNA extraction. How can such an enzymatic approach be performed in a remote site without a cold chain?

Briefly, we request a revised manuscript. It is written such that the reader must already be familiar with a previous paper published by the authors, of which this is an extension to detect variants. The manuscript should be stand alone and include all information about this assay and the method validation result. As the title of this manuscript is "detection of variants on a paper strip", generalizability must be addressed if this assay is able to do that. If not, the authors must discuss how to achieve generality and revise the title to "detection of common SARS-CoV-2 variants". In this scenario, the results can support the title.

We thank the Senior and Reviewing Editors of eLife for the positive and helpful suggestions and for considering that this tool has immediate application in healthcare during the current pandemic. We are now submitting a revised manuscript taking care of the points raised by the reviewers, both in terms of a better description of the technology and its modifications and improvements alongside commenting on the generalizability of the assay in the Discussion section. We accept the suggestion made about the title and have amended the same in the new version.

Reviewer 1:

Researchers from different groups have employed CRISPR-Cas9 protein variants (Cas13, and Cas12a) to develop nucleic acids detection platforms such as SHERLOCK (2017, Science, 356, 438; 2018, Science, 360, 439) and DETECTR (2018, Science, 360, 436). Both SHERLOCK and DETECTR rely on the "collateral effect" – promiscuous cleavage and degradation of neighboring ssRNA and ssDNA by Cas13 and Cas12a. Upon target binding, it will cleave the ssDNA probe. These CRISPR-based detections were used for SARS-CoV-2 detection after then (2020, Nature Biotechnology, 38, 870).

Authors previously reported that Francisella novicida (FnCas9) could be used for gene editing. In authors' preprint project, they reported the high specificity of FnCas9 to the point mismatch at the specific position of gRNA and there is no "collateral effect" of FnCas9. Based on this discovery, they developed a non-cleavage, affinity-based method for the nucleobase detection with single nucleotide mismatch sensitivity (ref 25).

Authors leverage the single nucleotide mismatch sensitivity of FnCAS9 and report herein a non-cleavage, affinity-based SARS-CoV-2 variants detection.

Strengths:

– This assay provides a simple, rapid way to detect SARS-CoV-2 and its SNV.

– Authors demonstrated the detection of SARS-CoV-2 and SARS-CoV-2 variants (N501Y) in 18 patient samples and validated the samples by sequencing.

Weaknesses:

– Although authors cite their previous preprint paper (similar assay called "FELUDA"), authors didn't describe any sensing mechanism of this assay (RAY). Readers cannot understand this assay by reading this manuscript only. The lack of description in this manuscript strongly affects readers to understand the experiments. Authors assume readers have read another article from the same group and understand the design and mechanism of their "FELUDA" assay. For example, Authors didn't mention that active FnCas9 was used in the experiment in Figure 2a while catalytic inactive FnCas9 was used for SNV detection assay "RAY".

We thank Reviewer 1 for his/her assessment of the assay and appreciating its ability to detect SNVs that constitute the VOCs in the SARS-CoV-2 genome. We understand the concerns raised by the Reviewer about the description of the sensing mechanism of RAY and the lack of clarity about the active/inactive versions of the FnCas9 used in Figure 2a. In the revised version we have made changes reflecting a detailed explanation of the assay and its modifications and included a comprehensive Supplementary Note describing the assay implementation.

– Only N501Y detection was demonstrated in this project. Authors did not demonstrate the generalizability of this assay by demonstration of detecting other SARS-CoV-2 variants. Furthermore, authors mentioned that only 10/32 SNV sites were targetable by FnCas9.

We thank Reviewer 1 for this point. Although we achieved the design of a RAY strategy for multiple variants, we couldn't validate them all due to time and sample availability constraints (as not all the variants were detected in the samples that were sequenced). However, we picked three of the reported VOCs in the samples we had access to (namely N501Y, E484K, and T716I) and validated RAY on patient RNA samples. We were able to detect all three variants using our assay successfully. We chose to perform intensive validation and standardization with N501Y over a larger sample set owing to its common occurrence across multiple lineages (Figure 4).

The Reviewer has rightly mentioned about 10/32 SNV sites that were targetable by FnCas9 in our original submission. Due to the rapid progress and evolution of the SARS-CoV-2 virus, currently (as of May 2021), 13 emerging lineages have been reported (Figure 1B, revised manuscript). Out of these, 5 lineages have been designated as Variants of Concern (VOCs) and 8 lineages as Variants of Interest (VOIs) by the Centers for Disease Control and Prevention (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Interest). We reanalyzed the emerging lineages and found that there are 48 SNVs associated with these VOCs and VOIs and RAY design based on existing parameters can target 19 of these SNVs. Importantly, RAY is able to detect every VOC/VOI through at least one SNV. We represent this data in Supplementary Table 1 and Figure 1 (revised manuscript).

Interestingly, N501Y is associated with 3/5 VOCs (B.1.1.7, P.1, and B.1.351). Thus, by detecting this variant, RAY can detect whether a sample belongs to one of these VOCs. In the remaining VOCs (B.1.427 and B.1.429) RAY for the SNV W152C SNV can be used in detection. However, this has not been practically validated.

– The concept / sensing mechanism of this assay is very similar to the assay reported in the same group (ref 25). They used a lot of results / discovery in the preprint (ref 25) to develop this assay and there are only 4 sets of new data reported in this manuscript.

We thank the Reviewer for this point but would politely disagree. Although the sensing mechanism occurs through FnCas9 and as was described before (Azhar, Phutela, Kumar, Ansari, et al. Biosensors and Bioelectronics, 2021), the current manuscript shows the detection of SARS-CoV-2 VOCs on a paper strip, which in our opinion, is both novel and has a high translational impact. Currently, identifying SARS-CoV-2 variants from patient samples exclusively relies on deep sequencing that is both costly and time-consuming. Thus, the value of this manuscript goes beyond simple discovery to a more useful public resource methodology which we hope gets implemented on a larger scale. To enable this paper-strip readout that is robust and performs with high sensitivity and specificity required several rounds of iteration and modification of the original FELUDA protocol and cannot be seen as an extension of the previous work.

There are several points that may help authors to improve this project.

"We found that out of the 32 defining SNVs 100 reported across all the three lineages, 10 sites were targetable by FnCas9 (Figure 1B,C, Supplementary Table 1)"

Figure 1B shows the evolution of SARS-CoV-2 virus. How is it related to this statement? Figure 1C shows the position of different mutations in the genome. Why is it important to show the position of the mutations? Is it related to the targetability of FnCas9? Explanation is needed.

We thank the Reviewer for pointing this out. We agree that Figure 1B does not appropriately correlate with the statement made and has now been replaced in the revised manuscript. We have also explained this better in the manuscript and hope that these modifications will help understand the targeting scope of RAY.

Authors should explain how they find 10 of 32 single nucleotide variation (SNV) sites are targetable by FnCas9. Why only 10/32 SNV sites are targetable? Authors should explain this result. Without this explanation, readers will not understand how this assay works and how to use this assay to detect other SNV.

As only 10 of 32 SNV sites are targetable, authors should discuss the generalizability of this assay.

We thank the Reviewer for this point. The mechanism by which FnCas9 based identification of SNVs has now been explained in detail in the revised manuscript (Figure 1 and Methods). We have also included a statement about the generalizability of this assay in the discussions section and made an amendment to the manuscript title to reflect this.

"Thirdly, we made modifications at the level of amplicon length, PCR conditions, and RNP concentration to generate the most optimal protocol that can produce a clear discernible signal on a commercially available paper strip"

No data is shown about PCR conditions and RNP concentration optimization. Why does the assay not work well when the amplicon length is 541 bp or less?

In my view, the combination of the preprint paper (ref 25) and this manuscript will make it a detailed, comprehensive project.

We thank the Reviewer for pointing this out. In the revised manuscript, we have demonstrated the conditions for optimization in Figure 3 and Figure 4. We have also discussed the importance of amplicon length on RAY performance in the manuscript and included a detailed protocol as Supplementary Note 1.

There are additional points that need addressing to improve this paper.

Only N501Y detection was demonstrated in this paper strip assay. Paper strip detection of other targetable SNV sites could show the generalizability of this assay in specific conditions.

We thank the reviewer for pointing this out. We have now demonstrated the detection of 2 more SNVs (E484K and T716I) in addition to N501Y on paper strips to show that several SNVs can be targeted through RAY (Figure 4G-H, revised manuscript).

This manuscript has a lot of abbreviations, but some of them only appear 1 or 2 times. It makes this manuscript difficult for readers to read.

It is confused that Wt, mut and N501Y are all present in Figure 2a. Authors are suggested to label it more clearly to show that it is WT and mutated sgRNA (N501Y).

"Finally, we tested RAY on RNA extracted from samples of RT-PCR positive SARS-CoV-2 infected individuals who returned to India from the United Kingdom between December 2020 and January 2021."

The travel history of the patient is not necessary for assay validation.

We thank the reviewer for mentioning these points. In the revised manuscript, we have taken care to refer to abbreviations judiciously and have removed the travel history information from the main manuscript text as suggested.

Reviewer 2:

The authors report the development of a CRISPR diagnostic platform for detecting variants (N501Y and T716I) in SARS-CoV-2. This is based on a technology, recently developed by the same research groups, using a Cas9 ortholog from Francisella novicida (FnCas9) based enzymatic readout for detecting nucleotide sequences. RAY (Rapid variant Assay), detect both the infection as well as the presence of the common N501Y mutation present in the 3 new variants and distinguish it from the parent CoV-2 lineage. The authors also adapt RAY to a lateral flow paper strip assay for low-cost rapid detection. This represents a novel sequencing-free rapid detection system for CoV2 mutations.

Although the paper does have major strengths in principle, the authors have not provided sufficient data and information directly for an end user to adapt this platform to their use. For a stand-alone resource article, authors must provide all the critical information within the text, figures, methods and supplementary figures required to understand the range, specificity, sensitivity, limits and error prone aspects (if any) of the technology.

We are grateful to Reviewer 2 for appreciating the technology and critically evaluating the work. We value the concerns raised for providing detailed information within the text, figures, methods, and supplementary figures for better implementation of the assay by an end-user. We have now addressed each of these points in detail in the revised manuscript.

Further information and clarification are required for the following points:

Primer design and selection:

1. Given that the authors mention that they successfully established that FnCas9 is unable to bind or cleave targets having two mismatches -in the 2nd and 6th position; why were PAMs searched with mismatches in the 16th and 19th position (Figure 1D)?

2. How many pairs of flanking primers need to be designed for a specific point mutation? What experimental output would demonstrate optimal primer design?

3. More details on the amplicons are required.

We thank Reviewer 2 for pointing this out. We have addressed these as follows:

1. The PAM search from the 16th and 19th positions was done based on our observation that the combination of these positions could also allow the FnCas9 to discriminate between its targets. In the revised manuscript, we have shown the in vitro cleavage outcomes for both 2 and 6 and 16 and 19 mismatched positions (Figure 1A). We apologize for not including this crucial piece of data in the original version.

2. A single primer pair of flanking primers are needed for a specific point mutation. The experimental output that demonstrates optimal primer design is the distinct difference in band intensities between the WT and SNV samples. In the revised manuscript, we have explained the methodology for smartphone-based evaluation of band intensities and subsequently calling the samples WT or Mutant.

3. We have provided details of the amplicon design in the revised manuscript.

IVC Detection

1. What size fragments were generated? Was only one sgRNA used for each N501Y and T716I?

In figure 2a it seems like the amount of wild type amplicon is higher or equal to one of the cleaved fragments in the N501Y sample gel (mut lane). Is this due to poor cleavage by the FnCas9? A densitometry analysis would provide better quantification of fragment formations.

We have indicated the size of the fragments in the revised manuscript (Figure 2A). Two different sgRNAs were used for N501Y and T716I correspondingly. The sequences of these sgRNAs are provided in Supplementary Table 4 in the revised manuscript. Densitometric analysis showed 72% cleavage of the mutant substrate and 3% cleavage of the WT substrate for N501Y and 83% and 1% respectively for T716I. Taken together this shows that the mismatch containing sgRNAs are highly specific in distinguishing the two substrates. In the revised manuscript, we have shown the outcome of T716I only as a lateral flow assay for clarity (Figure 4G).

2. What is the specificity, selectivity for each of these variants? Do altering sgRNA change the specificity? What conditions are necessary for the reaction to go to completion? How does one account for false negatives; is there a low copy number limit for this detection system. No experimental results have been provided for any of this.

3. For the reaction between FnCas9 and sample/amplicons what are the ratio ranges; concentrations; volumes to be followed?

The specificity and selectivity of these variants are high. In the revised manuscript, we present data from 37 WT and 22 N501Y samples and observe a sensitivity of 86 % and specificity of 97 % on LFA (Figure 4 in the revised manuscript). Since the discrimination of SNVs through RAY follows a design based on introducing mismatches, the possibility of alteration in sgRNA doesn’t arise since the mismatch positions are fixed with reference to the mutation.

For both the PCR and the subsequent CRISPR reaction, the presence of components (primers, enzymes, buffers, etc.) are in excess (details in Supplementary Note 1), and therefore the reaction proceeds to completion. In our previous study (Azhar, Phutela, Kumar, Ansari, et al. Biosensors and Bioelectronics, 2021), we had optimized the time required for the FnCas9 based substrate-binding reaction to proceed to completion. In this manuscript, we have adapted the same reaction time for RAY.

As seen in the revised manuscript (Figure 4E, F), false-negative results arise when the test band intensity is not high enough for visual/app-based detection. This can happen when the viral load is extremely low or the PCR efficiency is not optimal. Alternatively, a very low-intensity band can also be due to degradation of the CRISPR components in the assay (dFnCas protein or sgRNA).

The limit of detection expressed as a corresponding RT-PCR Ct value has now been presented in the revised manuscript (Figure 4E).

LFA Detection

1. Please elaborate the protocol for "modified single step" RT-PCR.

We provide a detailed protocol of the modified PCR and LFA steps in Supplementary Note 1.

2. The authors mention that they eliminate one of the biotin label primers to reduce the chances of background signal due to non-specific interactions of the unused biotin primers with the streptavidin. The authors should compare and quantitate the output using various methods used in the current work as well as previous FELUDA paper [double biotin labels; synthetic phosphothioate modified RNA etc]

We thank Reviewer 2 for pointing this out. We have now addressed all the points raised (single vs. double biotin labels) in Figure 4 of the revised manuscript. In our earlier study, we found that phosphorothioate modified synthetic sgRNAs have better stability as compared to in vitro synthesized sgRNAs over multiple rounds of freeze-thaw. Indeed, the same was observed when we performed RAY with phosphorothioate modified N501Y sgRNAs (Figure 4I).

3. Authors should explain the difference between FnCas9 and dFnCas9 in at least the methods.

We express regret for not clarifying this point well in the initial submission. We have now explained the difference clearly in the revised manuscript.

4. What are the limits of detection of RAY? Is it similar to FELUDA? How does changing sgRNA/ chimeric gRNA effect the detection limit? No experimental results have been provided for this.

We thank Reviewer 2 for raising this point. We would like to explain that RAY is an assay for discriminating between two samples (WT and mutant strains of the virus) while FELUDA is for detecting the viral RNA in a single patient sample. Thus for FELUDA, direct quantification of the limit of detection was possible (up to a Ct value of 38, Biosensors and Bioelectronics, 2021). For RAY, we performed serial dilutions of the WT and mutant strains (N501Y) and found that it was able to discriminate the two accurately up to a Ct value of 34. We have presented this data in Figure 4E (revised manuscript).

5. If the only method of detection analysis is TOPSE then the authors must provide more details of how to access/use the app.

We thank the reviewer for mentioning this. We have now described the TOPSE based acquisition and final interpretation in Supplementary Note 1. The application has been uploaded to a web server, and details about accessing the app have also been included.

Reviewer 3:

The work by Kumar et al. presents a new diagnostic technique (called "RAY") for detecting SARS-CoV-2 virus infection (responsible for the current COVID-19 pandemic). The researchers use a CRISPR-based method to provide a "quick" assay that can distinguish COVID positive and negative samples. This method is an extension of their previous work on a COVID-19 assay called FELUDA (https://www.medrxiv.org/content/10.1101/2020.09.13.20193581v1). The focus of the current work is to specifically identify COVID-positive samples as well as the particular variant of the viral genome. Typically, the different SARS-CoV-2 variants could differ by a few differences in the genome sequence. This work uses the specificity of the CRISPR reaction: the enzymatic cleavage only occurs for a completely complementary target and not for a target with mutations. The authors developed a lateral flow assay, where the signal corresponding to detection of the viral RNA and/or the mutant is read out as a line on a paper strip (similar to pregnancy strips). Appearance of these lines indicate presence of the virus in the sample. The work used 8 COVID positive samples, 8 positive samples with the mutation N501Y (earlier shown to be present in the British, South African and Brazilian variants of SARS-CoV-2), and 12 COVID negative samples, and identified all the clinical samples accurately.

In terms of the scope, the current work demonstrates COVID19 mutation detection with an easy lateral flow-based readout, within ~75 minutes. While the assay has been shown to be able to detect 20 samples accurately, a larger data set might be needed to evaluate the sensitivity of the assay and the range of viral loads it can detect. The past year has seen a number of new techniques for COVID19 diagnosis, all of which will be useful for the still ongoing large-scale testing worldwide. In that context, this assay has practical and immediate use for COVID19 detection if it can be commercialized, especially with the rise of a number of variants of the SARS-CoV-2 virus.

I liked reading the paper – it was very clear and crisp, and the data was well presented in both the text and the figures. However, as written, the paper seems to rely heavily on the reader's knowledge of their earlier work on FELUDA. From a reader's point of view, I felt that certain aspects of the assay, methodology and scope of immediate use could be expanded here even if it is a repeat from the authors' FELUDA work, to make this a stand-alone paper.

We thank Reviewer 3 for appreciating our work and commenting that the assay has practical and immediate use for COVID19 detection if it can be commercialized. The prime objective for this study is to develop an assay that can detect variants rapidly bypassing the cost and time associated with sequencing, and we are happy to report that we are in talks with interested parties for the global deployment of this assay.

We appreciate the Reviewer’s concerns about expanding more about the assay, methodology, and immediate use. We have now addressed each of these points in the revised version of the manuscript.

Discussion can be included on the following points. While these are not technical concerns, I think it will be informative for scientific and lay audience to know where the assay stands in terms of immediate impact for COVID19 pandemic.

–Metrics of the assay such as sensitivity and specificity (even if referring to previous works).

We thank Reviewer 3 for this point. We have now performed this assay on a larger sample size and have included the sensitivity and specificity metrics of the assay in the revised version of the manuscript (Figure 4E, F).

– Scope of the assay: Do the authors intend to use this as a clinical test or at POC? Specific aspects can be discussed for either or both of these scenarios.

We intend to use this test for rapid early screening of variant signatures. The pipeline of the RAY assay requires a PCR machine and can therefore be done in clinical labs. It then again can be extended to become a POC test in combination with isothermal amplification. Since the FELUDA protocol has been shown to work with Recombinase Polymerase Amplification (RPA), we foresee that adapting RAY to POC-like settings is possible. As Reviewer 3 suggested, we have now discussed these scenarios in the manuscript.

– For the assay to be useful in POC setting, sample processing is an important step. Assuming samples are collected on swabs, RNA needs to be extracted before RAY can be performed. How can this be brought into the regular workflow for the assay to work at a testing site outside a lab or clinical facility? How will this affect the cost of the assay? The tally of the assay cost excludes RNA extraction. How can such an enzymatic approach be performed in a remote site without a cold chain?

The Reviewer has correctly raised the point about RNA extraction being required for the assay. Currently, the original version of the assay (called FELUDA) is being done in lab settings. Since RNA requires careful handling, we do not foresee how this can be avoided except where an automated system for RNA extraction and subsequent assay steps can be set up. If this is successful, the test can be performed outside a lab or clinical facility.

We have not included the cost of RNA extraction since the assay has been tested with samples obtained by both columns, automated as well as column-free extraction methods. Since the costs associated with each vary a lot, we have kept the extraction methods separate from the tally.

Author details

1. Manoj Kumar

   1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
   2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

   Contribution

   Conceptualization, Data curation, Formal analysis, Writing - review and editing

   Contributed equally with

   Sneha Gulati

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-0772-1399

2. Sneha Gulati

   1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
   2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

   Contribution

   Conceptualization, Data curation, Formal analysis, Writing - review and editing

   Contributed equally with

   Manoj Kumar

   Competing interests

   No competing interests declared

3. Asgar H Ansari

   1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
   2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

   Contribution

   Resources, Formal analysis

   Competing interests

   No competing interests declared

4. Rhythm Phutela

   1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
   2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

   Contribution

   Data curation

   Competing interests

   No competing interests declared

5. Sundaram Acharya

   1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
   2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

   Contribution

   Data curation

   Competing interests

   No competing interests declared

6. Mohd Azhar

   1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
   2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

   Contribution

   Investigation, Methodology

   Competing interests

   Mohd. Azhar is currently an employee of TATA Medical and Diagnostics

7. Jayaram Murthy

   1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
   2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

   Contribution

   Investigation

   Competing interests

   No competing interests declared

8. Poorti Kathpalia

   1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
   2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

   Contribution

   Resources

   Competing interests

   No competing interests declared

9. Akshay Kanakan

   CSIR-Institute of Genomics & Integrative Biology, Mathura, India

   Contribution

   Data curation

   Competing interests

   No competing interests declared

10. Ranjeet Maurya

    1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
    2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

    Contribution

    Data curation

    Competing interests

    No competing interests declared

11. Janani Srinivasa Vasudevan

    CSIR-Institute of Genomics & Integrative Biology, Mathura, India

    Contribution

    Data curation

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-3381-5228

12. Aparna S

    CSIR-Institute of Genomics & Integrative Biology, Mathura, India

    Contribution

    Data curation

    Competing interests

    No competing interests declared

13. Rajesh Pandey

    1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
    2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

    Contribution

    Formal analysis, Supervision

    Competing interests

    No competing interests declared

14. Souvik Maiti

    1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
    2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India
    3. CSIR-National Chemical Laboratory, Pune, India

    Contribution

    Conceptualization, Funding acquisition, Methodology, Project administration, Writing - review and editing

    For correspondence

    souvik@igib.res.in

    Competing interests

    No competing interests declared

15. Debojyoti Chakraborty

    1. CSIR-Institute of Genomics & Integrative Biology, Mathura, India
    2. Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, India

    Contribution

    Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing

    For correspondence

    debojyoti.chakraborty@igib.in

    Competing interests

    A patent application has been filed in relation to this work. (0127NF2019).

    "This ORCID iD identifies the author of this article:" 0000-0003-1460-7594

• 4,212

  Page views

• 624

  Downloads

• 34

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.